1st Quarter - Amendment

KOUNTOUPES DENHAM CARR & REID, LLC for TEVA PHARMACEUTICALS USA, INC.

Firm
Client
Income
$40,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 20, 2017 $40,000 Replaced
1st Quarter - Amendment (this page) Apr 20, 2017 $40,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Issues related to comprehensive tax reform and the proposed border adjustment tax.

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

H. R. 1628-American Health Care Act: Medicaid Rebate provision of the Bipartisan Budget Act of 2015; Proposals related to affordability and pricing of pharmaceuticals including draft Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; H. R. 2051 - FAST Generics Act; S.771- Improving Access to Affordable Drugs Act; S.469-Affordable and Safe Prescription Drug Importation Act: and H. R. 749-Lower Drugs Through Competition Act. Issues related to industry user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement.

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2051 (115th), H.R. 1628 (115th), S. 771 (115th), S. 469 (115th), H.R. 749 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.